Leukemia

CStone Pharmaceuticals on Tuesday announced that its CEO Jason Yang plans to buy up to HK$5 million worth of the company’s shares in the open market over the next six months.

FAST NEWS: CStone says CEO to boost company holdings

The latest: CStone Pharmaceuticals (2616.HK) on Tuesday announced that its CEO Jason Yang plans to buy up to HK$5 million ($640,000) worth of the company’s shares in the open market over the…
2616.HK

Recent Articles

RELATED ARTICLES

  1. The share price fell nearly 40% in a week after this drugs company was dropped from a scheme allowing mainland investors to trade Hong Kong-listed stocks.
    Stock disconnect triggers investor exodus from CStone Pharma
    2616.HK
  2. CStone breaks up with drugs partner as U.S. rollout stalls
    2616.HK
  3. FAST NEWS: CStone drug approved for treatment of advanced non-small cell lung cancer
    2616.HK
  4. FAST NEWS: CStone licenses PD-1 cancer drug to 3SBio for China
    2616.HK
  5. CHINA BULLETIN: Bring on the Equipment Upgrades, Says Beijing
  6. AstraZeneca pays hefty price for Chinese weight-loss drug
    AZN.US
  7. HBM gets health boost from drug licensing deals
    2142.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners